Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

Running, not enrolling · Phase 3

Conditions studied: Renal Cell Carcinoma

In brief

This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial). The goal of this clinical research study is to learn if dynamic contrast enhanced computed tomography (DCE-CT) scans can help researchers learn if the study drug received as part of study 2010-0085 (either everolimus, bevacizumab, or pazopanib) is working.

Key facts

Study ID

NCT01224288

Run by

M.D. Anderson Cancer Center

People needed

120

Starts

2011-01-05

Expected to finish

2029-04-30

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must be enrolled or being considered for enrollment on protocol 2010-0085.
• Patients must have metastatic renal cell carcinoma (RCC).
• Age >/= 18 years.
• Subjects must have adequate renal function as defined by serum creatinine < 1.5x upper limit of normal.

You may not qualify if…

• Radiotherapy: Subjects may not have received prior radiotherapy to the index lesion within 4 weeks
• Female subjects who are pregnant or lactating.
• Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment).
• Allergy to CT contrast media requiring the administration of steroid prophylaxis.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.